⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 1, 2024The Quarterly Journal of Nuclear Medicine and Molecular Imaging

Correlation of FDG PET/CT, tumor markers and Ki-67 index with EGFR mutation or positive ALK expression in patients with non-small cell lung cancer

Hui Wang Zhi M Wang Wei Hu Xiao Q Liang Lan L Cui

View Full Paper

Ask AI

Bookmark

Share

Abstract

Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are the two most common druggable targets in non-small cell lung cancer (NSCLC). To investigate whether the EGFR mutation and ALK rearrangement could be predicted by the combination of FDG avidity, tumor markers and Ki-67 Index.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e61dfeb6db6435875b02e9 https://doi.org/10.23736/s1824-4785.24.03535-0

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1<b>Frequency of EGFR mutation and EML4-ALK fusion genes in patients with non-small cell lung carcinoma</b>2024
2Distinction of <scp><i>ALK</i></scp> fusion gene‐ and <scp><i>EGFR</i></scp> mutation‐positive lung cancer with tumor markers2024 · 5 citations
3131P FDG PET-CT as an imaging biomarker in predicting the molecular profile of treatment-naïve NSCLC2024
4Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma2025
5Correlation analysis between EGFR gene mutation status, ALK positivity and demographic data, tumor biomarkers, radiological and pathological features in patients with lung adenocarcinoma2025